The a2 Milk Company Limited (ACOPF) Q4 2025 Earnings Call Transcript

The a2 Milk Company (ACOPF) reported robust FY25 results, with record sales of $1.9 billion and double-digit growth across revenue (+13.5%), EBITDA (+17%), and EPS (+21%), while declaring a $0.20/share dividend. A significant strategic pivot was announced: the $282 million acquisition of Yashili New Zealand, providing critical China label market access and vertical integration, coupled with the divestment of its MVM stake for $100 million to optimize assets. This supply chain transformation is projected to drive future value, with the acquired facility becoming EBITDA breakeven by FY27, and the company forecasting high single-digit revenue growth and a 15-16% EBITDA margin for FY26, alongside an intended $300 million special dividend.

Analysis

The a2 Milk Company reported exceptionally strong FY25 results, with record revenue of $1.9 billion, a 13.5% year-over-year increase, driven by a 17% rise in EBITDA and a 21% jump in EPS. This performance was underpinned by the China and Other Asia segment, where total Infant Milk Formula (IMF) sales grew 10%, with English label sales surging 17%. The company solidified its market position, advancing to the #4 brand in the China IMF market with an 8% overall share, a notable achievement given the broader Chinese market contracted by 5.6%. Concurrently, the company announced a transformative strategic pivot involving the acquisition of the Yashili New Zealand facility for $282 million and the divestment of its stake in Mataura Valley Milk (MVM) for approximately $100 million. This transaction is critical as it provides immediate access to two additional China label (SAMR) registrations, addressing a key strategic gap where a2 was the only top-10 brand with a single China label product. While the new facility is projected to be loss-making in FY26 ($30-35 million EBITDA loss) and breakeven in FY27, management expects it to generate over $100 million in incremental sales by FY30. For FY26, the company guided for high single-digit revenue growth on a continuing operations basis and an EBITDA margin of 15-16%, reflecting the initial integration costs. The balance sheet remains robust with over $1 billion in net cash, supporting a declared $0.20 per share dividend for FY25 and a planned $300 million special dividend, signaling confidence in future cash flow despite significant investment.

Key Decisions for Investors

• The acquisition of the Pokeno facility is a significant strategic de-risking move that addresses the company's critical under-exposure to the China label market, and investors should view the near-term costs as a necessary investment for a stronger long-term growth trajectory.
• Expect a temporary compression in the EBITDA margin to the guided 15-16% range in FY26; however, monitor progress towards the FY27 breakeven target for the new facility and the in-sourcing of a2 Platinum as key catalysts for future margin expansion.
• Execution risk is now a primary focus, specifically the ability to secure regulatory approvals for rebranding the acquired China label slots within the projected 12-month timeline and the successful management of the complex operational transition.
• The planned $300 million special dividend, on top of the existing generous dividend policy, underscores strong balance sheet health and provides a significant capital return that may support valuation during the integration period.